Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00660803
Recruitment Status : Completed
First Posted : April 17, 2008
Last Update Posted : January 21, 2010
Dendrix - Scientific Information Architecture
Information provided by:

Brief Summary:
Characterize the demographic and clinical features, as well as the main treatment results, among patients with advanced breast cancer treated with fulvestrant in Brazil.

Condition or disease Intervention/treatment
Breast Cancer Drug: Fulvestrant

Study Type : Observational
Estimated Enrollment : 200 participants
Time Perspective: Retrospective
Official Title: Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer
Study Start Date : May 2008
Actual Primary Completion Date : April 2009
Actual Study Completion Date : April 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Fulvestrant

Group/Cohort Intervention/treatment
Postmenopausal women with hormone-receptor positive, advanced breast cancer who have failed at least one previous endocrine therapy and who have been treated at any one of the participating centres with fulvestrant.
Drug: Fulvestrant
Other Name: Faslodex

Primary Outcome Measures :
  1. Time to tumour progression
  2. Objective response

Secondary Outcome Measures :
  1. Duration of treatment with fulvestrant
  2. Time and duration of response
  3. Overall survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
hospitals and primary care clinics

Inclusion Criteria:

  • Positive HR or ER by immunohistochemistry
  • Postmenopausal status at the time of treatment with fulvestrant
  • Failure of at least one previous endocrine therapy before treatment with fulvestrant.

Exclusion Criteria:

  • Patients who are still undergoing treatment with fulvestrant will not be eligible to participate in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00660803

Research Site
Recife, PE, Brazil
Research Site
Rio de Janeiro, RJ, Brazil
Research Site
Porto Alegre, RS, Brazil
Research Site
Sao Paulo, SP, Brazil
Sponsors and Collaborators
Dendrix - Scientific Information Architecture

Responsible Party: Jose Eduardo Neves - Medical Science Director, AstraZeneca Identifier: NCT00660803     History of Changes
Other Study ID Numbers: NIS-OBR-FAS-2007/1
First Posted: April 17, 2008    Key Record Dates
Last Update Posted: January 21, 2010
Last Verified: January 2010

Keywords provided by AstraZeneca:
Advanced Breast Cancer
Hormone Therapy

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs